A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis
Status:
Not yet recruiting
Trial end date:
2025-02-28
Target enrollment:
Participant gender:
Summary
A study to investigate bowel urgency in adults with moderately to severely active ulcerative
colitis (UC) treated with mirikizumab. The study will have 4 periods and will last for 36
weeks.